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Abstract
Enhanced production of a 42-residue beta amyloid peptide (Ab42) in affected parts of the brain has been suggested to be
the main causative factor for the development of Alzheimer’s Disease (AD). The severity of the disease depends not only on
the amount of the peptide but also its conformational transition leading to the formation of oligomeric amyloid-derived
diffusible ligands (ADDLs) in the brain of AD patients. Despite being significant to the understanding of AD mechanism, no
atomic-resolution structures are available for these species due to the evanescent nature of ADDLs that hinders most
structural biophysical investigations. Based on our molecular modeling and computational studies, we have designed
Met35Nle and G37p mutations in the Ab42 peptide (Ab42Nle35p37) that appear to organize Ab42 into stable oligomers. 2D
NMR on the Ab42Nle35p37 peptide revealed the occurrence of two b-turns in the V24-N27 and V36-V39 stretches that could
be the possible cause for the oligomer stability. We did not observe corresponding NOEs for the V24-N27 turn in the Ab21–
43Nle35p37 fragment suggesting the need for the longer length amyloid peptide to form the stable oligomer promoting
conformation. Because of the presence of two turns in the mutant peptide which were absent in solid state NMR structures
for the fibrils, we propose, fibril formation might be hindered. The biophysical information obtained in this work could aid in
the development of structural models for toxic oligomer formation that could facilitate the development of therapeutic
approaches to AD.
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Introduction
The molecular pathology of Alzheimer’s disease (AD) is
characterized by increased accumulation of 39 to 43 residue long
beta-amyloid peptides (Ab) in plaques in the brains of Alzheimer’s
disease (AD) patients. Interestingly, individuals of nearly all ages
have moderate amounts of matured amyloid peptide fibrils present
in their brains, but only a certain percentage of them develop AD.
Previous work in this area has indicated that the presence of
oligomeric forms (amyloid-derived diffusible ligands, ADDL) of
the 42 residue beta-amyloid peptides, rather than fibrils, are
responsible for the neuronal damage and synaptic plasticity in the
central nervous system in AD [1,2]. It has also been shown that the
severity of neuronal damage is well correlated with the ADDL
content of Ab peptides in the Alzheimer’s diseased brain [3].
Monomers of the wild type form of Ab42 (Ab42WT) associate
into unstructured assemblies with variable aggregation numbers
[4,5]. Both oligomers and fibrils originate from these unstructured
intermediates. Ultimately, ADDLs are unstructured intermediates
leaving only matured fibrils as the most stable entities [6,7]. Much
effort has been undertaken to probe the Ab fibril state utilizing
solid-state NMR [8], X-ray [9], Cryo EM [10], electron
microscopy [11], neutron scattering [12], atomic force microscopy
[13] and other spectroscopic methods [14,15].
Very little is known about the structure of the ADDL form of
the beta-amyloid peptide. The inherent formation of higher order
aggregates by Ab is a great challenge for the experimental
characterization of ADDLs. Researchers working in this area are
hampered by the difficulties of obtaining sufficient concentrations
of ADDL for spectroscopic measurements [16]. Efforts have been
made to search for means to stabilize the oligomeric, ADDL,
species. For example, Wetzel et al. and others have identified small
molecules that stabilize the Ab42WT in the proto-fibrillar forms
[17,18]. The work of Selkoe et al. [19] comparing neurotoxic
properties of Ab42WT and the Arctic mutant E22G Abs, proposed
that the stability of ADDLs is inversely correlated to the nucleation
rate of the formation of fibrillar aggregates. Using photo-induced
cross-linking and gel electrophoresis, Bitan et al. suggested the
predominant ADDL species of Ab42WT are monomers, dimers,
trimers, pentamers, and hexamers [20]. They have also observed
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species in the oligomerization pathway. A predominantly ADDL
forming mutant of Ab is yet to be known in the literature.
Based on our earlier in silico modeling studies, and supported by
other work suggesting the formation of b–strand character in the
C-terminus of Ab, we propose an Ab variant with two point
mutations (Met35 to norleucine, and Gly37 to D-proline) to form
stable, soluble oligomers [21,22,23]. Previous work has demon-
strated the ability of single substitutions in the Ab sequence to alter
stability and morphology of Ab assemblies [24]. First, we
substituted the isosteric norleucine in place of Met35 to act as a
non-perturbing replacement which would remove issues that could
result from the variability of the oxidation state of Met35.
Secondly, we substituted a D-proline for G37 in order to stabilize
the oligomeric structure seen in simulations, i.e. a C-terminal beta
hairpin with a turn at residues 37–38 [23]. In this paper, we probe
structural properties of Ab42Nle35p37 and its truncated version
Ab21–43Nle35p37 using different biophysical techniques. In
particular, we have used Nuclear Magnetic Resonance (NMR)
spectroscopy to determine structural properties of ADDL form,
and finally use this data in molecular modeling to refine observed
structural features.
Results
Mutant peptide Ab42Nle35P37 forms stable oligomers in
solution
In a previous computational study, Kelley et al hypothesized that
a turn promoting mutation such as G37p would stabilize trimeric
Ab oligomers [23]. In agreement with this prediction, the mutant
peptide, Ab42Nle35p37, was found to adopt a significantly higher
yield of soluble oligomer than that of Ab42WT. This is seen in the
one-dimensional
1H NMR spectra of Ab42WT (Figure 1A) and
Ab42Nle35p37 (Figure 1B) for samples prepared in the same
manner. The Ab42WT spectrum has very little observable signal
consistent with the peptide having precipitated from solution (no
signal to detect) and/or formed very large molecular weight
aggregates (significant line-broadening). Whereas the same
spectral region for Ab42Nle35p37 shows amide and aromatic
resonances characteristic of soluble, non-aggregating peptides/
proteins.
Conformational analyses of the mutant and Ab42WT peptides
were also carried out by Circular Dichroism (CD) spectroscopy. A
representative CD trace of Ab42WT aggregate is observed to
develop into b-sheet rich, mature fibrils over a period of 12 hours
with the characteristic strong absorbance at ,220 nm (Figure 2,
Curve WT). However, in the case of the Ab42Nle35p37 mutant,
no change was observed in the CD spectrum after one week.
Figure 2, Curve Mut shows the CD spectrum of Ab42Nle35p37
having a strong absorbance around 197 nm typical of random-
coil, disordered states in solution.
Thioflavin T fluorescence was used to assess aggregation and
mature fibril formation as b-sheet content is directly correlated
with fluorescence intensity of the dye. We observed about four
times more Thioflavin T fluorescence in the Ab42WT peptide
when compared to Ab42Nle35p37 (Figure 2 inset) confirming the
aggregating and non-aggregating nature of the WT and mutant
peptides, respectively.
High-resolution analysis of the peptide solution preparations
were carried out using atomic force microscopy (AFM). Figure 3
shows AFM images of the soluble form of Ab42WT and
Ab42Nle35p37 peptide preparations deposited onto clean silicon
wafers. The wafers for Ab42WT wildtype preparations showed
particles with a mean globular structure height of 4.32 nm but
with a variation of particle sizes ranging from 2.06 to 14.79 nm.
Notably, particles appeared to be adhered to each other or
connected by thin fibrils suggesting they were in the process of
forming larger aggregates. The wafers for the Ab42Nle35p37
mutant preparations showed particles with a similar mean globular
structure height of 4.00 nm compared to wildtype, however the
distribution of heights was much smaller at 2.29 to 4.84 nm. This,
along with the relatively uniform density of globular structures
observed, suggests the mutant peptide is stabilized in smaller
oligomers.
Identification of turns and hairpins in Ab42Nle35p37 and
Ab21–43Nle35p37 by NMR
Having demonstrated that the full-length mutant Ab42Nle35p37
peptide forms assumes a stable, low-molecular weight form in
solution we proceeded with multi-dimensional NMR experiments
on the mutant peptide. The quality of two-dimensional
1H-
1H
TOCSY and NOESY spectra were marginal due to signal overlap
and line-broadening (Figure 4ABC) likely caused by a combination
of low-level aggregation, conformational heterogeneity, and
conformational averaging between transiently structured confor-
mations.
In order to aid the assignment problem, we built on previous
work suggestive that the N-terminal residues of the Ab sequence
are flexible and unstructured by working with a truncated form of
the mutant peptide, Ab21–43Nle35p37 [23,25]. When HFIP film of
this truncated mutant peptide was dissolved, we observed higher
Figure 1. One-dimensional NMR proton spectra of Ab peptides.
Aromatic/amide regions of A) Ab42WT and B) Ab42Nle35p37 in 10%
DMSO/PBS, pH 7.2, at 25uC.
doi:10.1371/journal.pone.0021776.g001
Figure 2. CD spectroscopy of the Ab42Nle35p37 and Ab42WT
peptides. Ab42WT takes beta-sheet rich fibrils (curve WT) while
Ab42Nle35p37 shows a large negative peak around 197 nm indicating
disordered structure (curve Mut). Thioflavin T fluorescence of Ab42WT
and Ab42Nle35p37 peptides are shown in the inset. Data was measured
at 25uC.
doi:10.1371/journal.pone.0021776.g002
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(,1 mg/ml). This truncated peptide remained in solution without
any fibril formation, similar to the full-length mutant, for a period
of more than 6 months (data not shown).
The TOCSY and NOESY spectra of the truncated peptide
gave slightly better quality data (Figure 4DEF) when compared to
the full-length mutant peptide. Assignments, though not trivial,
were more tractable on this construct. Working with the
information gleaned from the truncated form allowed a degree
of validation for the full-length mutant assignments (the spectral
profiles showed similarities though not one-for-one overlays).
Interestingly, save for Y10 and K16, the N-terminal residues in the
full-length mutant peptide, Ab42Nle35p37, were not readily
assigned, consistent with the N-terminus being flexible and
unstructured. Assignments are given in Tables 1 and 2 for
Ab42Nle35p37 and Ab21–43Nle35p37, respectively.
A wealth of significant NOE crosspeaks was not expected from
these peptides but the few that we observed were rather
interesting. Comparative intensities of NOEs for Ha-NH (i, i+1)
and Ha-NH (i, i) are indicative of turn conformation [26,27,28].
Specifically, residues that have extended conformation show
higher Ha-NH (i, i+1) NOE intensity compared to that of Ha-NH
(i, i), while residues involved in turn conformation show higher
Ha-NH (i, i) intensity than the corresponding Ha-NH (i, i+1)
intensity. For the full length mutant Ab42Nle35p37 peptide, Ha-
NH (i,i) NOE cross peaks are observed for G25-S26 and G38-
V39. Also observed are NH-NH (V24-G25) and NH-NH (G25-
S26) NOEs suggesting a type I turn in the region of V24-N27. Ha-
NH (p37-G38) and NH-NH (G38-V39) NOEs suggest that the
p37-G38 segment forms a type II9 b-turn. The Ha-Hd (V36-p37)
cross peak observed between V36 and p37 indicates that p37 is in
the trans conformation. Earlier work on Ab42WT monomers
suggests turns around D7-Y10 and V24-N27 [29,30]. Our data
supports the existence of this second turn. Though we do not
observe the first turn, we cannot discount the possibility of its
presence being very transient in nature given the difference in
spectral properties observed between the full-length and truncated
mutant peptides.
Figure 4. Two-dimensional NMR proton spectra of Ab peptides.
2D
1H-
1H spectra of Ab42Nle35p37 (A, B, C) and Ab21–43Nle35p37 (D, E,
F). TOCSY of (NH-Ha) region of the Ab42Nle35p37 (A) and Ab21–
43Nle35p37 (D). NOESY of (NH-Ha) region of Ab42Nle35p37 (B) and
Ab21–43Nle35p37 (E). NOESY of (NH-NH) region of Ab42Nle35p37 (C) and
Ab21–43Nle35p37 (F). Data was measured at 15uC in 10% DMSO-d6, PBS,
pH 7.2.
doi:10.1371/journal.pone.0021776.g004
Figure 3. AFM images of Ab peptide preparations. A) Represen-
tative 1.061.0-mm x-y, 10-nm total z-range AFM micrograph of Ab42WT
preparation. Observed are irregularly shaped and sized aggregate
particles, some connected by fibrils. B) A surface plot of the boxed
region of (A) clearly showing the aggregate with connected fibril.
C) Representative 1.061.0-mm x-y, 10-nm total z-range AFM micrograph
of Ab42Nle35p37 preparation showing discrete globular aggregates of
uniform size and density.
doi:10.1371/journal.pone.0021776.g003
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full-length mutant, we observed Ha-NH (p37-G38) and NH-NH
(G38-V39) NOE cross peaks suggesting a type II9 b-turn involving
residues V36-V39. Similarly, an Ha-Hd (V36, p37) cross peak
suggests the presence of trans conformation for p37. We do not
observe NH-NH NOEs for the turn around V24-N27, but this
may be the result of N-terminal flexibility in this truncated
construct.
Results from computational structure refinement
Refinement via molecular dynamics using the NMR constraints
was used to produce an ensemble of structures for the NOE
containing regions of the full length mutant Ab42Nle35p37
peptide. (Figure 5, PDB S1 and PDB S2) We see the existence
of two definite turns – the D-proline induced beta-hairpin (residues
V36-V39) and a more N-terminal turn consisting of residues V24-
N27, which is in agreement with the available SS-NMR fibril
studies and complimentary unconstrained MD simulations
[6,31,32,33].
Mutant peptide decreases fibril content of WT aggregate
mixtures
Ab42WT was found to adopt a soluble oligomeric form to a
much greater extent when mixed with the mutant. By co-
solubilizing Ab42WT with Ab42Nle35p37 in 1:4 and 4:1 ratios, the
mixtures resulted in one-dimensional
1H NMR spectra very
similar to that acquired on Ab42Nle35p37 alone (Figure 6AB). To
ensure the spectra observed were not simply the result of all
Ab42WT precipitating, oligomerizing, or aggregating to itself
leaving only mutant Ab42Nle35p37 peptide observable by NMR,
we also produced the same WT: mutant peptide mixtures using
uniformly
15N-labeled Ab42WT. We were able to observe resolved
1H{
15N} HSQC spectra (Figure 6C) verifying the ability of the
mutant peptide stabilizing the WT in solution, and suggesting that
the mutant peptide could act as an inhibitor to fibril formation of
Ab42WT. Acquiring two-dimensional TOCSY experiments on the
mixture samples found similarities in CaH chemical shifts to the
mutant peptide alone (Figure 6D) suggestive that the Ab42WT
adopts a similar conformation to the Ab42Nle35p37 mutant when
the two are mixed.
Discussion
In our effort to design a soluble oligomer-forming mutant, we
have previously predicted that the mutation of G37p will result in
enhanced b hairpin formation and increased oligomer stability.
Two-turn structures were obtained using NOE refinement. The
occurrence of the first turn at V24-N27 is in agreement with the
available SS-NMR fibril studies. The second turn consisting of
residues V36-V39, absent in previous studies, is introduced here
by the mutation. In the nucleated polymerization model fibrils are
likely to grow by monomer addition [34]. The two-turn structure
of the mutant possibly depletes monomer content by diverting
peptide into a stable oligomer formation.
Earlier NMR studies showed that Ab monomers adopts a
collapsed coil (mostly random) with a well-defined central
hydrophobic cluster (L17-A21) and turn- or bend-like structures
(D7-E11 and A21-S26) [35]. The data presented here are
consistent with these previous observations. Additionally, we have
Table 1. Chemical shift assignments of Ab42Nle35p37.
Amino acid NH aH bH Others
Y10 8.02 4.554 2.95, 3.08
K16 8.242 4.317 1.554, 1.662 dH 1,405
E22 8.18 4.355 2.218
D23 8.349 4.672 2.685
V24 8.379 4.292 1.806 cH 0.9618
G25 8.143 4.01
S26 8.203 3.927 4.484
N27 8.339 4.616 3.063
K28 8.475 3.97 - eH 2.293
G29 8.64 3.898
A30 8.082 4.366 1.406
I31 8.165 4.196 1.909 eH 0.9618
I32 8.627 4.17 1.9 eH 0.9591
G33 8.602 4.026
L34 8.143 4.445 1.627 -
NL35 8.301 4.63 1.616 cH1.227, eH1.105
V36 8.7 4.583 2.021 cH 0.9852
dP37 4.22 2.39 cH 2.081, 2.143
dH 3.885
G38 8.494 3.791
V39 7.88 4.3 2.12 cH 0.94
V40 8.488 4.235 2.248 cH 0.9513
I41 8.678 4.291 2.016 eH 0.981
A42 7.989 4.36 1.401
doi:10.1371/journal.pone.0021776.t001
Table 2. Chemical shift assignments of Aß21–43Nle35p37.
Amino acid NH aH bH others
E22 8.543 4.743 1.92 cH 1.268
D23 8.47 4.455 2.795
V24 8.275 4.17 1.873 cH 0.926
G25 8.418 3.788
S26 8.214 3.9 4.451
N27 8.644 4.661 2.682
K28 8.464 4.665 1.978,1.885 cH 1.423 eH2 . 8
G29 8.616 3.993
A30 8.068 4.333 1.374
I31 8.179 4.172 1.874 cH 1.202 eH 0.889
I32 8.54 4.218 1.91 eH 0.93
G33 8.464 3.949
L34 8.141 4.428 1.642 dH 0.9494
NL35 8.242 4.675 1.606
V36 8.648 4.537 2.023 cH 0.957
dP37 4.423 2.373 cH 2.006 , 2.1
dH 3.892
G38 8.401 3.97
V39 7.853 4.274 2.88 cH 0.92
V40 8.446 4.487 1.98 cH 0.9118
I41 8.314 4.168 2.191 cH 0.9655
A42 8.442 4.178 1.418
doi:10.1371/journal.pone.0021776.t002
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et al. have also studied the structure of the oxidized form of
Met35
ox Ab40 and Ab42 peptides in aqueous Tris-HCl buffered
solutions at pH 6.4–8.2 [36]. They showed unstructured peptide
strands punctuated by turns around S8-V12 and F20-V24 regions.
Their
15N{
1H} NOE data showed that the Ab42Met35
ox has
reduced flexibility at the C-terminus relative to the Ab40 Met35
ox
suggesting insipient structure around this region, consistent with
our hypothesis of a beta hairpin in the same region.
How does this structural data compare to previous SS-NMR
data studies on fibril structure? Almost all fibrillar studies show a
hairpin turn forming somewhere between residues 24 and 30.
Examining three of the most recent and notable studies, we find
three different sets of amino acids forming the turn location,
although it is arguable that this may be attributed to the
differences in information content for the various methods and
their corresponding sensitivity to structural disorder [6]. Ohman’s
2006 study of residues 1–42 predict a turn consisting of residues
25–28 or GSNK in the sequence [31]. Riek’s predicted turn of the
same chain is shifted two amino acids towards the N-terminus at
residues 27–30 and sequence NKGA [32]. Tycko’s recent work
concerning Ab40WT has found a turn at residues V24-N27 with
sequence VGSN [6]. This turn location is in agreement with our
oligomer data. Moreover, our ensemble highly resembles an
unconstrained MD study of the same chain, in which the ensemble
was clustered and the most populated node was presented [33].
Our refined ensemble shows a less static ensemble than the SS-
NMR fibril studies. The d-Pro induced turn at residues V36-V39
disrupts the inter-chain contacts present in the fibril models by
changing the monomer topology. This leaves the VGS turn sequence
to stabilize itself exclusively via intra-chain contacts, and we suggest
this to be the reason we see greater flexibility in this region.
The AFM data for the mutant Ab42Nle35p37 peptide suggest
that it forms predominantly low molecular weight species in
solution. The 4 nm mean AFM particle height would be in the
range of five- to eight-mer complexes by a statistical analysis
performed by Lobanov et al. on the radius of gyration of .3500
protein domains in the SCOP database [37]. But notably, the
domains in the Lobanov study were compact, folded, a and/or b
containing proteins. The likelihood of the Ab mutant peptide
being in a loose, predominantly undefined structure, would
possibly reduce the number of monomer units present per
complex.
Conclusions
The data presented in this paper indicate the structurally
disordered oligomeric assemblages of Ab42WT and mutant differ
in their propensity to form oligomers and fibrils. Ab42WT peptide
formed fibrils at the concentration of 0.4 mM at 10% DMSO/
PBS. The mutant preparation resulted entirely in low molecular
weight entities. NMR studies on Ab42Nle35p37 showed occur-
rence of two b-turns in the stretches V24-N27 and V36-V39.
Upon mixing Ab42Nle35p37 mutant with Ab42WT, Ab42WT
peptide is stabilized in solution suggesting a significant reduction in
fibril formation. Presumably such reduced fibril formation is due
to the engineered b-turn of the mutant (V36-V39) hindering the
formation of the C-terminal b-turn (V24-A30) found in the fibril
SS-NMR structure. Although our finding implies the existence of a
stabilizing structure for the ADDLs in the mutant peptide, we were
not able to detect any known secondary structure stretches, other
than the two b-turns, by
1H-NMR and CD spectroscopy. This
suggests that b-sheet or a-helix formation is not required for the
ADDL stability. Finally, the ability of this mutant to inhibit the
aggregation of WT Ab peptide opens a door to another use for this
mutant peptide, since a variant of this peptide or a small molecule
peptide mimic could potentially serve as a means to inhibit Ab
aggregation.
How are these results useful in gaining insight into the nature of
WT Ab? While our NMR structural data of the mutant does not
directly give structural data regarding the WT, the fact that the
mutant mixed with the WT has slowed aggregation suggests that
the C terminal beta hairpin presumably stabilized by the mutant
does have structural relevance for understanding the nature of the
aggregation of WT Ab. Future work could either use the C
terminal beta hairpin motif for small molecule drug discovery in
order to find novel small molecule inhibitors of Ab aggregation.
Materials and Methods
Sample preparation
Synthetic peptide Ab42Nle35p37 of the sequence DAEFRHDS-
GY
10EVHHQKLVFF
20AEDVGSNKGA
30IIGL
NLV
DpGVV
40IA
Figure 5. NOE refinement ensembles. 5 structures were taken at
1 ns intervals from the computational structure refinements. Shown are
the six residues around the turns (solid color rendering for the four
residues around the turns, semi-transparent for the leading and trailing
residues), backbone heavy-atoms shown for all residues, and side-chain
heavy-atoms included for the four residues around the turns. (A) The
V24-N27 turn is observed in most SS-NMR studies, and as show here has
a conformation similar to previous unconstrained MD simulations. (B)
The induced beta-turn from the d-Pro mutation, V36-V39, is clearly
defined.
doi:10.1371/journal.pone.0021776.g005
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AEDVGSNKGA
30IIGL
NLV
DpGVV
40IAT (Ab21–43Nle35p37) was
synthesized and purified by the Stanford Protein and Nucleic Acid
Facility. Recombinant purified Ab42WT, both unlabeled and
15N-
labeled, peptides (.95%) were obtained from rPeptide (Bogart, GA).
All peptides were used as supplied. Solution samples of the peptides
were prepared as follows. Peptides were dissolved in 1,1,1,3,3,3-
hexafluoro-2-propanol (HFIP) to concentrations of 1 mM HFIP,
evaporated over nitrogen, and then dried in a Savant Speed Vac for
1 hr. The resultant peptide films were further kept under vacuum for
a few hours to remove solvent traces. The films were stored at 280uC
until use. Peptide films were dissolved to ,0.5 mM concentrations in
10% d6-DMSO/10 mM PBS buffer to a final pH of 7.2. The
solutions were incubated at 4uC for 12 hours, and then transferred to
37uC for 4 hours. The resulting solutions were centrifuged at
13000 rpm in a desktop centrifuge (Eppendorf) at 4uCf o r3 0m i nt o
remove any precipitated gel-form of the peptides. After centrifuga-
tion, the peptide concentrations were adjusted to 0.4 mM (concen-
trations were checked by UV visible spectroscopy), 0.05% sodium
azide added as a bacteriostat and transferred to 5 mm NMR tubes.
Mixtures (4:1 and 1:4) of Ab42Nle35p37:Ab42WT (total peptide
concentration of 1 mM) were prepared in HFIP. The solvent was
evaporated using speed-vac and resultant peptide films were dissolved
in 10% d6-DMSO/10 mM PBS buffer and processed as above.
d6-DMSO was purchased from Cambridge Isotope Labora-
tories (Cambridge, MA). Tris(2,29-bipyridyl)dichloro ruthenium(II)
(Ru(Bpy)) and ammonium persulfate (APS) were purchased from
Sigma.
Figure 6. One- and two-dimensional NMR spectra of Ab peptide mixtures. 1D proton spectra of the aromatic/amide regions of 1:4 (A) and
4:1 (B) mixtures of Ab42Nle35p37:Ab42WT. (C) 2D
1H-
15N HSQC (Heteronuclear Single Quantum Coherence) experiment of the 4:1
Ab42Nle35p37:Ab42WT mixture (Ab42WT uniformly
15N-labeled), in 10% DMSO/PBS, pH 7.2, at 25uC. (D) 2D
1H-
1H TOCSY (NH-Ha) region of the 4:1
Ab42Nle35p37:Ab42WT mixture, in 10% DMSO/PBS, pH 7.2.
doi:10.1371/journal.pone.0021776.g006
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binding studies
Ab42Nle35p37, having been dissolved and processed above
(10% DMSO/PBS buffer), was passed through a 10/30 Superdex
75 HR column to remove DMSO and immediately analyzed by
CD. An Ab42WT sample was prepared into PBS buffer in order to
demonstrate a representative beta-sheet rich CD trace. The fibrils
from the Ab42WT preparation were centrifuged at 12000 rpm for
15 min to separate from any remaining monomer and the pellet
was re-suspended in 10 mM phosphate pH 7.2 for CD measure-
ment. CD measurements were performed using a 0.1 mm path
length quartz cell in an Aviv 62A DS Circular Dichroism
spectrometer (Aviv Associates, Lakewood, NJ) at 22uC.
Mean residue ellipticity (h) was determined according to the
equation h=hObs N MRW/(10 N l N c); where hObs is observed
ellipticity, MRW is mean residue weight of the peptide, c is peptide
concentration (g/L), and l is optical path length (cm). The
thioflavin T (ThT) binding studies of Ab42WT and mutant
peptides were carried out by incubating precipitated fibrils of the
Ab42WT or eluted oligomer preparation from the SEC column.
The 25 mM amyloid fibrils (Ab42WT) or oligomers of mutant were
mixed with 5 mM of ThT dye concentration. After 2 h incubation,
the fluorescence of the sample solutions were recorded by exciting
at 440 nm and the intensity at 480 nm is monitored using Perkin-
Elmer LC 55B spectrofluorimeter. The bandwidths of excitation/
emission wavelengths were 5 nm/each.
Atomic Force Microscopy
AFM topography images were acquired in the light tapping
mode regime using a Multimode AFM (Veeco, USA). Resonant
frequencies of the uncoated silicon tips (MikroMasch, USA) were
roughly 150 kHz, with scan rates around 5–8 mm/s. Peptide
samples were prepared using the protocol described above and
diluted to 25 mM before application. Peptide solutions were
adsorbed by incubating onto Pirahna cleaned silicon wafers with
molecular smoothness (,1A ˚ RMS roughness) as determined by
AFM. After incubating for 10 min, the wafers are gently washed
repeatededly with MilliQ water.
NMR Spectroscopy
NMR spectra were acquired at the Stanford Magnetic
Resonance Laboratory on a Bruker Avance 500 MHz spectrom-
eter running TopSpin v1.3 and equipped with a 5 mm H{CN} Z-
axis gradient CryoProbe. Peptide samples were prepared as
described above in 10% d6-DMSO/10 mM PBS buffer of pH 5.5
or 7.2. One-dimensional
1H experiments were acquired with
16384 total data points, 12 ppm spectral window, and number of
scans ranging from 64 to 256. Two-dimensional
1H-
1H TOCSY
(TOtal Correlation SpectroscopY) experiments were acquired with
2048 total data points, 11 ppm spectral windows, 60 or 80 ms
dipsi2 mixing times, for 256 to 512 increments of 32 to 128 scans
per increment. Two-dimensional
1H-
1H NOESY (Nuclear Over-
hauser Effect SpectroscopY) experiments were acquired with 2048
total data points, 11 ppm spectral windows, 100, 150, 200 or
400 ms mixing times, for 128 increments of 128 scans per
increment. The two-dimensional
1H-
15N HSQC (Heteronuclear
Single Quantum Coherence) experiment was acquired with 1024
total data points, 12 ppm (
1H) and 40 ppm (
15N) spectral windows,
for 128 increments of 256 scans per increment. Sample
temperatures were regulated from 15 to 30uC. Water suppression
was accomplished with WATERGATE in each experiment. The
data was processed in TopSpin and analyzed with SPARKY [38].
Computational Structure Refinement
Atomic level structures for the 2 predicted turns were obtained
using molecular dynamics. Chains of eight amino acids long at the
site of each turn were created in an extended coil conformation.
Each chain was capped with an acetyl group on the N-terminus
and a N-methyl on the C-terminus to avoid any termini
association due to charge effects. Chains were then solvated with
tip3p water in a dodecahedral box, with dimensions allowing a
1.5 nm separation between peptide atoms and the edge of the box.
After an energy minimization, a harmonic potential was added
based on the NOE data. The spring constant for this potential was
set to 1250 kJ/mol, and applied outside of the accepted range of
0.5 nm, with a truncation creating a constant maximum force
beyond 0.6 nm. NOE distances were allowed to fluctuate and
updated every 10 ps, allowing the capability for multiple
constraints on each atom. Forces contributing to the hydrogen-
bond distances were applied at every step for a more rigid
network. The peptides were simulated using Gromacs and the
Amber 2003 force field [39,40,41,42]. After 3 ns equilibration
time, each system was run for 5 ns with structures taken every
1 ns, producing an ensemble.
Supporting Information
PDB S1 PDB file of five snapshots of the V24-N27 turn from
NMR refinement, as displayed in Figure 5a.
(PDB)
PDB S2 PDB file of five snapshots of the V36-V38 turn from
NMR refinement, as displayed in Figure 5b.
(PDB)
Acknowledgments
We thank Muralidhar Reddy Yerramadha and Zhenan Bao for technical
help and assistance.
Author Contributions
Conceived and designed the experiments: VSP JR CL. Performed the
experiments: JR CL MI ML PN. Wrote the paper: JR CL NK PN VSP.
References
1. Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration:
lessons from the Alzheimer’s amyloid beta-peptide. Nat Rev Mol Cell Biol 8:
101–112.
2. Perez de Vega MJ, Baeza JL, Garcia-Lopez MT, Vila-Perello M, Jimenez-
Castells C, et al. (2008) Synthesis and biological properties of beta-turned
Abeta(31–35) constrained analogues. Bioorg Med Chem Lett 18: 2078–2082.
3. Klein WL, Krafft GA, Finch CE (2001) Targeting small Abeta oligomers: the
solution to an Alzheimer’s disease conundrum? Trends Neurosci 24: 219–224.
4. Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, et al. (2003) Alzheimer’s
disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a
molecular basis for reversible memory loss. Proc Natl Acad Sci U S A 100:
10417–10422.
5. Ciccotosto GD, Tew D, Curtain CC, Smith D, Carrington D, et al. (2004)
Enhanced toxicity and cellular binding of a modified amyloid beta peptide with
a methionine to valine substitution. J Biol Chem 279: 42528–42534.
6. Petkova AT, Yau WM, Tycko R (2006) Experimental constraints on quaternary
structure in Alzheimer’s beta-amyloid fibrils. Biochemistry 45: 498–512.
7. Barghorn S, Nimmrich V, Striebinger A, Krantz C, Keller P, et al. (2005)
Globular amyloid beta-peptide oligomer - a homogenous and stable neuro-
pathological protein in Alzheimer’s disease. J Neurochem 95: 834–847.
8. Tycko R (2006) Molecular structure of amyloid fibrils: insights from solid-state
NMR. Q Rev Biophys 39: 1–55.
9. Serpell LC (2000) Alzheimer’s amyloid fibrils: structure and assembly. Biochim
Biophys Acta 1502: 16–30.
Ab Mutant Stabilizes b-Turn and Forms Oligomers
PLoS ONE | www.plosone.org 7 July 2011 | Volume 6 | Issue 7 | e2177610. Stromer T, Serpell LC (2005) Structure and morphology of the Alzheimer’s
amyloid fibril. Microsc Res Tech 67: 210–217.
11. Dong J, Apkarian RP, Lynn DG (2005) Imaging amyloid beta peptide
oligomeric particles in solution. Bioorg Med Chem 13: 5213–5217.
12. Yong W, Lomakin A, Kirkitadze MD, Teplow DB, Chen SH, et al. (2002)
Structure determination of micelle-like intermediates in amyloid beta -protein
fibril assembly by using small angle neutron scattering. Proc Natl Acad Sci U S A
99: 150–154.
13. Karsai A, Martonfalvi Z, Nagy A, Grama L, Penke B, et al. (2006) Mechanical
manipulation of Alzheimer’s amyloid beta1–42 fibrils. J Struct Biol 155:
316–326.
14. Nilsson KP, Aslund A, Berg I, Nystrom S, Konradsson P, et al. (2007) Imaging
distinct conformational states of amyloid-beta fibrils in Alzheimer’s disease using
novel luminescent probes. ACS Chem Biol 2: 553–560.
15. Yoshiike Y, Akagi T, Takashima A (2007) Surface structure of amyloid-beta
fibrils contributes to cytotoxicity. Biochemistry 46: 9805–9812.
16. Bitan G, Kirkitadze MD, Lomakin A, Vollers SS, Benedek GB, et al. (2003)
Amyloid beta -protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize
through distinct pathways. Proc Natl Acad Sci U S A 100: 330–335.
17. Williams AD, Sega M, Chen M, Kheterpal I, Geva M, et al. (2005) Structural
properties of Abeta protofibrils stabilized by a small molecule. Proc Natl Acad
Sci U S A 102: 7115–7120.
18. McLaurin J, Golomb R, Jurewicz A, Antel JP, Fraser PE (2000) Inositol
stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid beta
peptide and inhibit abeta -induced toxicity. J Biol Chem 275: 18495–18502.
19. Klyubin I, Walsh DM, Cullen WK, Fadeeva JV, Anwyl R, et al. (2004) Soluble
Arctic amyloid beta protein inhibits hippocampal long-term potentiation in vivo.
Eur J Neurosci 19: 2839–2846.
20. Bitan G, Lomakin A, Teplow DB (2001) Amyloid beta-protein oligomerization:
prenucleation interactions revealed by photo-induced cross-linking of unmod-
ified proteins. J Biol Chem 276: 35176–35184.
21. Sgourakis NG, Yan Y, McCallum SA, Wang C, Garcia AE (2007) The
Alzheimer’s peptides Abeta40 and 42 adopt distinct conformations in water: a
combined MD / NMR study. Journal of Molecular Biology 368: 1448–1457.
22. Wu C, Murray MM, Bernstein SL, Condron MM, Bitan G, et al. (2009) The
structure of Abeta42 C-terminal fragments probed by a combined experimental
and theoretical study. Journal of Molecular Biology 387: 492–501.
23. Kelley NW, Vishal V, Krafft GA, Pande VS (2008) Simulating oligomerization
at experimental concentrations and long timescales: A Markov state model
approach. J Chem Phys 129: 214707.
24. Paparcone R, Pires M, Buehler M (2010) Mutations Alter the Geometry and
Mechanical Properties of Alzheimer’s Ab(1–40) Amyloid Fibrils. Biochemistry
49: 8967–8977.
25. Williams AD, Portelius E, Kheterpal I, Guo JT, Cook KD, et al. (2004) Mapping
abeta amyloid fibril secondary structure using scanning proline mutagenesis.
J Mol Biol 335: 833–842.
26. Zhang X, Xu Y, Zhang J, Wu J, Shi Y (2005) Structural and dynamic
characterization of the acid-unfolded state of hUBF HMG box 1 provides clues
for the early events in protein folding. Biochemistry 44: 8117–8125.
27. Griffiths-Jones SR, Maynard AJ, Searle MS (1999) Dissecting the stability of a
beta-hairpin peptide that folds in water: NMR and molecular dynamics analysis
of the beta-turn and beta-strand contributions to folding. J Mol Biol 292:
1051–1069.
28. Griffiths-Jones SR, Sharman GJ, Maynard AJ, Searle MS (1998) Modulation of
intrinsic phi,psi propensities of amino acids by neighbouring residues in the coil
regions of protein structures: NMR analysis and dissection of a beta-hairpin
peptide. J Mol Biol 284: 1597–1609.
29. Hou L, Shao H, Zhang Y, Li H, Menon NK, et al. (2004) Solution NMR studies
of the A beta(1–40) and A beta(1–42) peptides establish that the Met35 oxidation
state affects the mechanism of amyloid formation. J Am Chem Soc 126:
1992–2005.
30. Lazo ND, Grant MA, Condron MC, Rigby AC, Teplow DB (2005) On the
nucleation of amyloid beta-protein monomer folding. Protein Sci 14:
1581–1596.
31. Olofsson A, Sauer-Eriksson AE, Ohman A (2006) The solvent protection of
alzheimer amyloid-beta-(1–42) fibrils as determined by solution NMR
spectroscopy. J Biol Chem 281: 477–483.
32. Luhrs T, Ritter C, Adrian M, Riek-Loher D, Bohrmann B, et al. (2005) 3D
structure of Alzheimer’s amyloid-beta(1–42) fibrils. Proc Natl Acad Sci U S A
102: 17342–17347.
33. Baumketner A, Bernstein SL, Wyttenbach T, Lazo ND, Teplow DB, et al.
(2006) Structure of the 21–30 fragment of amyloid beta-protein. Protein Sci 15:
1239–1247.
34. Xue WF, Homans SW, Radford SE (2008) Systematic analysis of nucleation-
dependent polymerization reveals new insights into the mechanism of amyloid
self-assembly. Proc Natl Acad Sci U S A 105: 8926–8931.
35. Zhang S, Iwata K, Lachenmann MJ, Peng JW, Li S, et al. (2000) The
Alzheimer’s peptide a beta adopts a collapsed coil structure in water. J Struct
Biol 130: 130–141.
36. Riek R, Guntert P, Dobeli H, Wipf B, Wuthrich K (2001) NMR studies in
aqueous solution fail to identify significant conformational differences between
the monomeric forms of two Alzheimer peptides with widely different plaque-
competence, A beta(1–40)(ox) and A beta(1–42)(ox). Eur J Biochem 268:
5930–5936.
37. Lobanov M, Bogatyreva NS, Galzitskaia OV (2008) Radius of gyration is
indicator of compactness of protein structure. Mol Biol (Mosk) 42: 701–706.
38. Goddard TD, Kneller DG (2003) SPARKY 3. San Francisco: University of
California.
39. Ponder JW, Case DA (2003) Force fields for protein simulations. Adv Protein
Chem 66: 27–85.
40. Sorin EJ, Pande VS (2005) Exploring the helix-coil transition via all-atom
equilibrium ensemble simulations. Biophys J 88: 2472–2493.
41. Lindahl E, Hess B, Spoel Dvd (2001) GROMACS 3.0: a package for molecular
simulation and trajectory analysis. J Mol Model 7: 306–317.
42. Berendsen HJC, Spoel Dvd, Drunen Rv (1995) GROMACS: A message-passing
parallel molecular dynamics implementation. Computer Physics Communica-
tions 91: 43–56.
Ab Mutant Stabilizes b-Turn and Forms Oligomers
PLoS ONE | www.plosone.org 8 July 2011 | Volume 6 | Issue 7 | e21776